Back to results
US 2023/0141371 A1Published application
Coronavirus vaccines and methods of use
AssigneeBiontech US Inc.
InventorsRichard B. Gaynor, Lakshmi Srinivasan, Asaf Poran, Dewi Harjanto, Christina Kuksin, Daniel Abram Rothenberg, John Srouji
Life of this patent
Estimating the term…
Abstract
Compositions and methods for the prevention and/or treatment of a viral infection, in particular of the Coronaviridae family.
Claims98
A composition comprising:
- (i) a polypeptide comprising at least two of the following (a) a sequence comprising an epitope sequence from ORF1ab, (b) a sequence comprising an epitope sequence from membrane glycoprotein (M) and (c) a sequence comprising an epitope sequence from nucleocapsid phosphoprotein (N);
- (ii) a polynucleotide encoding a polypeptide, wherein the polypeptide comprises at least two of the following (a) a sequence comprising an epitope sequence from ORF1ab, (b) a sequence comprising an epitope sequence from membrane glycoprotein (M) and (c) a sequence comprising an epitope sequence from nucleocapsid phosphoprotein (N);
- (iii) a T cell receptor (TCR) or a T cell comprising the TCR, wherein the TCR binds to an epitope sequence of the polypeptide in complex with a corresponding HLA class I or class II molecule;
- (iv) an antigen presenting cell comprising (i) or (ii);
- or
- (v) an antibody or B cell comprising the antibody, wherein the antibody binds to an epitope sequence of the polypeptide;
- and
- a pharmaceutically acceptable excipient.
5 more elements
A pharmaceutical composition comprising:
- (i) a polypeptide comprising an epitope sequence of Table 1A, Table 1B, Table 1C, Table 2Ai, Table 2Aii, Table 2B and/or Table 16;
- (ii) a polynucleotide encoding the polypeptide comprising an epitope sequence of Table 1A, Table 1B, Table 1C, Table 2Ai, Table 2Aii, Table 2B and/or Table 16;
- (iii) a T cell receptor (TCR) or a T cell comprising the TCR, wherein the TCR binds to the epitope sequence in complex with a corresponding HLA class I or class II molecule;
- (iv) an antigen presenting cell comprising (i) or (ii);
- or
- (v) an antibody or B cell comprising the antibody, wherein the antibody binds to the epitope sequence;
- and
- a pharmaceutically acceptable excipient.
5 more elements
A pharmaceutical composition comprising:
- a polypeptide having an amino acid sequence with at least 70%, 80%, 90% or 100% sequence identity to a sequence of any one of the sequences depicted in column 2 of Table 11, column 2 of Table 12 or column 3 of Table 15;
- or a recombinant polynucleotide encoding a polypeptide having an amino acid sequence with at least 70%, 80%, 90% or 100% sequence identity to a sequence of any one of the sequences depicted in column 2 of Table 11, column 2 of Table 12 or column 3 of Table 15.
Dependencies are inferred from the claim text.